Pulmonary arterial hypertension（PAH） is a serious cardiovascular disease that causes progressive elevation of pulmonary artery pressure for a number of reasons, eventually leading to right heart failure and even death. In recent years, the use of targeted drugs developed for the pathogenesis of PAH has delayed the progress of this kind of patients to some extent, but its long-term prognosis is still very severe. Therefore, it is particularly important to find biomarkers which are closely related to the severity of the disease and can accurately predict the short-term and long-term prognosis of the disease. So far, brain natriuretic peptide（BNP）and N-terminal pro-brain natriuretic peptide (NT-proBNP) has been proved to reflect the severity and prognosis of the disease to a considerable extent, but soluble suppression of tumorigenicity 2 (sST2), as a new generation plasma marker of heart failure, is considered to be more objective and accurate to evaluate the severity and prognosis of the disease. In this paper, the research progress of BNP/NT-proBNP and sST2 in PAH is briefly reviewed.